Neuroprotective effects of a systemically active Group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia

Ann Bond(Eli Lilly (United Kingdom)), Michael J. OʼNeill(Eli Lilly (United Kingdom)), Caroline Hicks(Eli Lilly (United Kingdom)), James A. Monn(Eli Lilly (United States)), David Lodge(Eli Lilly (United Kingdom))
Neuroreport
April 1, 1998
Cited by 84

Abstract

The neuroprotective effects of a novel Group II metabotropic glutamate receptor (mGluR) agonist, LY354740, have been evaluated in a gerbil model of global ischaemia. When administered at 50 mg/kg, i.p., 30 min and 6 h after a 3 min period of bilateral carotid artery occlusion (BCAO), the compound reduced the damage to CA1 hippocampal neurones to a significant level. However, when the ischaemic insult was made more severe, by increasing the period of occlusion to 4 and 5 min, the neuroprotective effects of LY354740 were reduced. From these findings, it would appear that Group II mGluRs may play a role in ischaemic damage in the gerbil hippocampus and that agonists at these receptors are potential neuroprotective agents.


Related Papers

No related papers found

Powered by citation graph analysis